Otonomy to Report Second Quarter 2022 Financial Results and Provide Corporate Update

Rhea-AI Summary

Otonomy, Inc. (Nasdaq: OTIC) announced it will report its second-quarter 2022 financial results and provide a corporate update on July 25, 2022, at 4:30 p.m. ET. The event will be accessible via a live webcast on Otonomy's investor relations website, which will also archive the session for 30 days. Otonomy is focused on developing innovative therapeutics for neurotology, utilizing a unique drug delivery technology aimed at addressing hearing loss and tinnitus.

Positive

• Scheduled financial results reporting indicates ongoing operational transparency.
• The company has a focused pipeline addressing important unmet medical needs.

Negative

• None.

SAN DIEGO, July 18, 2022 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced it will report financial results for the second quarter 2022 and provide a corporate update at 4:30 p.m. ET on July 25, 2022. 

A live webcast of the call will be available online in the investor relations section of Otonomy’s website at www.otonomy.com and will be archived there for 30 days. To access the live call by phone, please go to this link (registration link), and you will be provided with dial-in details. To avoid delays, we encourage participants to dial into the conference call fifteen minutes ahead of the scheduled start time.

About Otonomy 
 
Otonomy is a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology. The company pioneered the application of drug delivery technology to the ear in order to develop products that achieve sustained drug exposure from a single local administration. This approach is covered by a broad patent estate and is being utilized to develop a pipeline of products addressing important unmet medical needs with a focus on hearing loss and tinnitus. For additional information, please visit www.otonomy.com. 

Contacts:

Media Inquiries:
Spectrum Science
Lauren Benton
Senior Account Executive
212.899.9731
lbenton@spectrumscience.com

Investor Inquiries:
ICR Westwicke
Robert H. Uhl
Managing Director
858.356.5932
robert.uhl@westwicke.com 

FAQ

When will Otonomy report its financial results for Q2 2022?

Otonomy will report its financial results for Q2 2022 on July 25, 2022, at 4:30 p.m. ET.

How can I access Otonomy's Q2 2022 financial results webcast?

The webcast for Otonomy's Q2 2022 financial results can be accessed on the investor relations section of Otonomy's website.

What is Otonomy's focus in biopharmaceuticals?

Otonomy is dedicated to developing innovative therapeutics for neurotology, specifically targeting hearing loss and tinnitus.

Will the Otonomy Q2 results be archived?

Yes, the webcast of the Otonomy Q2 results will be archived for 30 days on their website.